Mois : décembre 2019

A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems, Daniela da Fonseca Pacheco et al.,

A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems Daniela da Fonseca Pacheco, Ana Cristina Nogueira Freitas, Adriano Monteiro C. Pimenta, Igor Dimitri Gama Duarte and Maria Elena de Lima Journal of Venomous Animals and Toxins including Tropical Diseases, 2016, 22, 34, Doi : 10.1186/s40409-016-0091-6   Abstract Background : Some peptides purified from the venom of the spider Phoneutria nigriventer have been identified as potential sources of drugs for pain treatment. In this study, we characterized the antinociceptive effect of the peptide PnPP-19 on the central nervous system and investigated the possible involvement of opioid and cannabinoid systems in its action [...]

Lire la suite

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder, Beth Wiese and Adrianne R. Wilson-Poe, 2018

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder Beth Wiese and Adrianne R. Wilson-Poe Cannabis and Cannabinoid Research, 2018, Volume 3.1,179-189. Doi : 10.1089/can.2018.0022   Abstract Introduction : The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion : Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for [...]

Lire la suite

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial, Richard J. Zeifman et al., 2019

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325   Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]

Lire la suite

The Therapeutic Potentials of Ayahuasca in the Treatment of Depression, Fernanda Palhano-Fontes et al., 2014

The Therapeutic Potentials of Ayahuasca in the Treatment of Depression Fernanda Palhano-Fontes, Joao C. Alchieri, Joao Paulo M. Oliveira, Bruno Lobao Soares, Jaime E. C. Hallak, Nicole Galvao-Coelho and Draulio B. de Araujo Chapter 2, in B. C. Labate and C. Cavnar (eds.), "The Therapeutic Use of Ayahuasca", Springer-Verlag Berlin Heidelberg, 2014 Doi : 10.1007/978-3-642-40426-9_2,   Abstract Major depressive disorder (MDD) is generally classified as a mood disorder with a profound effect on the individual’s behavior and quality of life. According to the World Health Organization, in about 20 years, depression will be the disorder with the most significant repercussions, both socially and economically. Despite [...]

Lire la suite

Psilocybin-assisted therapy for depression : How do we advance the field ?, Sally E Meikle et al., 2019

Psilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575   Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]

Lire la suite

Cannabidiol Protects Dopaminergic Neuronal Cells from Cadmium, Jacopo Junio Valerio Branca et al., 2019

Cannabidiol Protects Dopaminergic Neuronal Cells from Cadmium Jacopo Junio Valerio Branca, Gabriele Morucci, Matteo Becatti, Donatello Carrino, Carla Ghelardini, Massimo Gulisano, Lorenzo Di Cesare Mannelli  Alessandra Pacini International Journal of Environmental Research and Public Health, 2019, 16, 4420. doi : 10.3390/ijerph16224420   Abstract The protective effect of cannabidiol (CBD), the non-psychoactive component of Cannabis sativa, against neuronal toxicity induced by cadmium chloride (CdCl2 10 M) was investigated in a retinoic acid (RA)-dierentiated SH-SY5Y neuroblastoma cell line. CBD (1 M) was applied 24 h before and removed during cadmium (Cd) treatment. In dierentiated neuronal cells, CBD significantly reduced the Cd-dependent decrease of cell viability, and the rapid [...]

Lire la suite

IACM-Bulletin du 06 Décembre 2019

IACM-Bulletin du 06 Décembre 2019 Science/Homme: Le cannabis riche en CBD pourrait être utile dans l'autisme Science/Homme: Le cannabis peut être utile dans le traitement de l'endométriose Science/Homme: Un extrait de chanvre riche en CBD peut réduire l'utilisation d'opiacés chez les patients souffrant de douleur chronique États-Unis: Un Comité de la Chambre des Représentants adopte un projet de loi historique visant à décriminaliser le cannabis Royaume-Uni: 20 000 patients bénéficieront d'un essai de cannabis médical En bref Un coup d'œil sur le passé Science/Homme: Le cannabis riche en CBD pourrait être [...]

Lire la suite

Endocannabinoid System, Aleksandra Tarasiuka et al., 2019

Endocannabinoid System Aleksandra Tarasiuka, Maciej Salagaa, and Jakub Fichna Encyclopedia of Gastroenterology, 2nd Edition, 2019 © 2019 Elsevier Inc. All rights reserved. https://doi.org/10.1016/B978-0-12-801238-3.65635-0 1   Introduction 1 Cannabinoids and Their Role in the Physiological and Pathophysiological Processes in the GI Tract 3 Physiological Conditions 3 Gut motility 3 Gastric secretion and emptying 3 Pathophysiological Conditions 4 IBS 4 IBD 5 Colon cancer 5 Peptic ulcer disease 5 Endocannabinoid System and Its Interplay With Other Systems 5 Cholecystokinin 5 Endovanilloids 6 Opioids 6 Endocannabinoid System and Gut Microbiota 6 Conclusion 7 Acknowledgments 7 References Introduction Endocannabinoid system (ECS) is one of the crucial physiological systems that may be targeted to improve human health. Endocannabinoids and their receptors are localized in various organs (heart, lungs, urinary bladder, [...]

Lire la suite

Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This : Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too) An Interview with Richard Yensen, Philip E. Wolfson, 2014

Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This : Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too) An Interview with Richard Yensen Philip E. Wolfson International Journal of Transpersonal Studies, 2014, 33, (2), 160-174.   Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from 1972 to 1976. He studied psychedelic psychotherapy with Stanislav Grof, M.D. and other senior staff. During this time he treated patients with substance abuse disorders, cancer, neurosis, and other health professionals seeking a training experience. Dr. Yensen did his Ph.D. dissertation on the use of MDA in [...]

Lire la suite